Adam Crystal, President, R&D at Tango Therapeutics, Inc. (TNGX), sold 38,460 shares at $25.00 ($962K) on 2026-04-15, disclosed to the SEC on 2026-04-16.
Scheduled sale ($962k) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TNGX | SELL | 2026-08-05 | $736K | — | Filing → |
| TNGX | SELL | 2026-07-02 | $799K | — | Filing → |
| TNGX | SELL | 2026-06-03 | $618K | — | Filing → |